Our team is thrilled to announce our participation in the H.C. Wainwright & Co., LLC @ Home Fireside Chat Series on December 3rd at 11:00 am ET. This event will be webcast, so you can join us from anywhere! Tune in for the latest updates on our progress towards a functional cure for chronic HBV. #HCW #cHBV #HBV ???Live Webcast: https://lnkd.in/gerki6NP
关于我们
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial.
- 网站
-
https://www.arbutusbio.com
Arbutus Biopharma Corporation的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Warminster，Pennsylvania
- 类型
- 上市公司
地点
-
主要
获取路线
701 Veterans Circle
US，Pennsylvania，Warminster，18974
Arbutus Biopharma Corporation员工
-
Ravi Dugyala
Executive Director of Toxicology at Arbutus Biopharma Corporation
-
Jin Miao
Quality Control Supervisor at Phyton Biotech
-
Richard Henriques
Board Member and Audit Committee Chair in Biotechnology and Philadelphia area non-profit organizations.
-
Kristi Fan
Drug Discovery | CADD | AIDD | Structure-based Drug Design | Computational Chemistry
动态
-
Arbutus Biopharma Corporation转发了
???????????? ???????????????????? ????????: Arbutus Biopharma Corporation's CEO (interim) Michael McElhaugh summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting. He describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen, saw a functional cure. Given this learning, he also discusses the potential development plan going forward. #TLM24 Full video: https://lnkd.in/g8r35dDc BiotechTV is brough to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Klein Hersh
-
We will be hosting meetings during J.P. Morgan 2025! Stay connected and reach out to [email protected] if you would like to schedule a meeting with our team. #chronicHBV #HBV #StayConnected
-
-
Tomorrow, Michael McElhaugh and David Hastings will be featured in a fireside chat at the Jefferies London Healthcare Conference. Tune in to the live webcast at 12:00 pm GMT / 7:00 am EST to hear the latest updates. Don’t miss it! #JefferiesHealthcare #cHBV #HBV ???Live Webcast: https://lnkd.in/g5ax7HNH
-
-
Arbutus Biopharma Corporation转发了
Today, we announced that we exceeded our HBV functional cure rate goal in our IM-PROVE I Phase 2a clinical trial. Imdusiran combined with a short course of interferon achieved a 50% functional cure rate in chronic HBV patients that had HBsAg <1000 IU/mL at baseline and a 25% functional cure rate overall. #cHBV #HBV #functionalcure ? ?? Full press release: https://lnkd.in/gc8JD2XS
-
-
Today, we announced that we exceeded our HBV functional cure rate goal in our IM-PROVE I Phase 2a clinical trial. Imdusiran combined with a short course of interferon achieved a 50% functional cure rate in chronic HBV patients that had HBsAg <1000 IU/mL at baseline and a 25% functional cure rate overall. #cHBV #HBV #functionalcure ? ?? Full press release: https://lnkd.in/gc8JD2XS
-
-
In collaboration with our partner Barinthus Biotherapeutics, today we announced data from the IM-PROVE II Phase 2a clinical trial, showing that imdusiran combined with VTP-300 and nivolumab increased rates of HBsAg loss in people with chronic Hepatitis B #cHBV #HBV #clinicaldata #HBsAgloss ? ?? Full press release: https://lnkd.in/gV-ccFwE
-
-
Our team is heading to the Jefferies London Healthcare Conference! We’ll be participating in a fireside chat and hosting one-on-one meetings on November 21st.?Don’t miss this opportunity to get updated on our progress towards a functional cure for chronic HBV. #chronicHBV #HBV #JefferiesHealthcare ?? Fireside Chat: November 21st at 12:00 pm GMT/ 7:00 am EST ???Live Webcast: https://lnkd.in/g5ax7HNH
-
-
Today, Dr. Karen Sims gave a presentation on our RNAi therapeutic, imdusiran, currently in two clinical trials for chronic HBV treatment. The presentation titled: Imdusiran Combinations Achieving HBsAg Loss in HBV, was delivered at the International Workshop on HBV Cure in San Diego. Thank you, Dr. Sims! https://lnkd.in/gtGzqZVP #HBVCure #cHBV #HBV
-
-
This Veterans Day, we salute the brave men and women who have served our country with courage and dedication. Your sacrifices and commitment to protecting our freedoms will never be forgotten. Thank you for your service. #VeteransDay #HonorOurHeroes
-